Similar study was conducted by Umbricht et al.—149 Tb-PSMA-617 was used for targeted α-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. Here, FOLH1 is linked to prostate cancer.